Mabwell has established an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation. The international standard drug discovery platforms and skillful & efficient development platforms enable us to develop innovative biologics efficiently and submit IND rapidly. We focus on large-scale, fast-growing therapeutic areas including auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Mabwell has 14 pipeline products. Of these, 2 products have been approved and commercialized, 1 product has been filed for MA approval, 1 product is in the preparation of filing, 2 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects.
Comply with GMP requirements in China, U.S., and Europe. Adopt both disposable and stainless-steel bioreactors for drug substance production. Our manufacturing capabilities in complex formulations covers a wide range of injectables for biological products across multiple delivery formats from vials to pre-filled syringes (PFS).
69,700 ㎡ (17 Acres)
Over 27,000L capacity
Digitize the entire production process, more efficiently, higher quality output
Capacity: 8,000L, antibody production; 4,000L, recombinant protein production
Have passed EU QP Audit
53,400㎡ (13 Acres)
Specialized in the production of ADCs & antibodies
